10-Q: INmune Bio Reports Q3 2024 Results, Cites Ongoing Losses and Funding Needs

INmune Bio's Q3 2024 report reveals continued losses and a need for additional funding to sustain operations.

Summary

• INmune Bio, a clinical-stage biotechnology company, reported a net loss of $32.9 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents decreased to $33.6 million as of September 30, 2024, from $35.8 million at the end of 2023.
• Operating expenses totaled $33.2 million for the nine-month period, with research and development accounting for $25.8 million.
• The company is developing two product platforms: DN-TNF for Alzheimer's and cancer, and INKmune for cancer.
• INmune Bio is currently conducting a Phase 2 trial for XPro in early Alzheimer's patients with biomarkers of inflammation.
• A Phase 1/2 trial of INKmune in metastatic castrate-resistant prostate cancer is also underway.
• The company has raised capital through the sale of common stock and warrants, including a registered direct offering in September 2024 that generated $12 million in net proceeds.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• The company is exploring various financing strategies, including public or private sales of equity, debt financing, and strategic alliances.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a decrease in cash reserves, and management's doubt about the company's ability to continue as a going concern. While there is progress in clinical trials, the financial instability and need for additional funding overshadow the positive developments.

Positives

• The company completed enrollment in the Phase 2 Alzheimer's trial in Q3 2024.
• The Phase 1/2 trial of INKmune in metastatic castrate-resistant prostate cancer is progressing with the third cohort expected to open in November 2024.
• The company successfully raised $12 million in net proceeds through a registered direct offering in September 2024.
• The company has a validated manufacturing process for mesenchymal stromal cells (CORDstrom).

Negatives

• The company incurred a net loss of $32.9 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents decreased to $33.6 million as of September 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has an ongoing dispute with a vendor regarding $1.2 million in invoices.
• The company terminated further enrollment in the MDS/AML trial due to recruitment difficulties.

Risks

• The company's recurring net losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• The company may not be able to secure additional financing on favorable terms, or at all.
• The company's product candidates are still in clinical trials and have not been approved by any regulatory authority.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company relies on a small number of vendors for manufacturing supplies and materials.
• Fluctuations in foreign exchange rates could adversely affect the company's financial results.
• The company has an ongoing dispute with a vendor which could result in further financial losses.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development efforts and seeks regulatory approvals for its product candidates. The company is exploring various financing strategies to secure additional funding.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding of future operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management believes that the company's DN-TNF platform can be used as a CNS therapy to target glial activation to prevent progression of Alzheimer's disease.
• Management believes that INKmune may be best used to eliminate residual disease after the patient has completed other cancer therapies.

Industry Context

The company operates in the competitive biotechnology industry, focusing on novel approaches to treating diseases by targeting the innate immune system. The company's focus on Alzheimer's and cancer aligns with significant unmet medical needs and ongoing research in these areas. The company's approach of selectively neutralizing soluble TNF is a unique strategy compared to non-selective TNF inhibitors.

Comparison to Industry Standards

• The company's financial results are typical of early-stage biotechnology companies that are heavily investing in research and development and have not yet generated significant revenue.
• The company's cash burn rate is high, which is common for companies in this sector that are conducting multiple clinical trials.
• The company's reliance on external funding is also typical of early-stage biotech companies.
• The company's focus on novel therapeutic approaches, such as targeting soluble TNF and priming natural killer cells, is consistent with current trends in immunotherapy and neurodegenerative disease research.
• The company's approach to Alzheimer's treatment, focusing on neuroinflammation, is aligned with current research in the field.
• The company's approach to cancer treatment, focusing on reversing resistance to targeted therapy, is aligned with current research in the field.
• The company's approach to cell therapy, focusing on mesenchymal stromal cells, is aligned with current research in the field.
• The company's approach to manufacturing mesenchymal stromal cells is unique and may provide a competitive advantage.

Legal Proceedings

• The company has an ongoing dispute with a vendor in which the Company believes that the vendor did not properly provide services for which they have invoiced the Company.

Related Party Transactions

• The company recorded $15,000 and $112,000, respectively, of prepaid expenses related party for payments made to UCL in advance of medical research to be provided.
• The company owed AmplifyBio $30,000 and $10,000, respectively, in connection with medical research performed on behalf of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and partners may be affected by the company's ability to continue its operations and development programs.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company plans to report top-line cognition data from the Phase II Alzheimer's trial approximately seven months after the last patient is enrolled.
• The company plans to report secondary endpoints from the Phase II Alzheimer's trial 2-3 months after top-line data.
• The company plans an end-of-phase II meeting with the FDA to finalize plans for the pivotal Phase III trial for Alzheimer's.
• The company expects to receive authorization to initiate a clinical trial in TRD during the second half of 2024.
• The company expects to complete enrollment in the Phase I/II trial of INKmune in metastatic castrate-resistant prostate cancer during the first half of 2025.
• The company plans to report data from each cohort of the Phase I/II trial of INKmune in metastatic castrate-resistant prostate cancer as it becomes available.

Key Dates

Keywords

INmune Bio, Biotechnology, Clinical Trials, Alzheimer's Disease, Cancer, Immunotherapy, XPro, INKmune, Financial Results, Going Concern, Capital Raise, Research and Development